{"id":"low-dose-tenecteplase-intravenous-thrombolysis","safety":{"commonSideEffects":[{"rate":"1-6","effect":"Intracranial hemorrhage"},{"rate":"2-5","effect":"Systemic bleeding"},{"rate":"<1","effect":"Angioedema"},{"rate":null,"effect":"Reperfusion injury"}]},"_chembl":{"chemblId":"CHEMBL2108791","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tenecteplase is a tissue plasminogen activator (tPA) variant engineered for improved fibrin specificity and longer half-life compared to alteplase. At reduced doses, it activates the fibrinolytic cascade to break down thrombi while potentially reducing systemic bleeding complications. Low-dose regimens aim to maintain efficacy in clot lysis while improving the safety profile in acute stroke management.","oneSentence":"Low-dose tenecteplase is a fibrin-specific thrombolytic agent that converts plasminogen to plasmin, dissolving blood clots in acute ischemic stroke.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:25.614Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke within therapeutic window"}]},"trialDetails":[{"nctId":"NCT07294209","phase":"PHASE4","title":"Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients","status":"RECRUITING","sponsor":"Southwest Hospital, China","startDate":"2025-12-19","conditions":"Acute Ischemic Stroke Patients","enrollment":798},{"nctId":"NCT06320431","phase":"PHASE3","title":"ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2024-09-26","conditions":"Acute Ischemic Stroke AIS, Stroke Acute, Stroke, Acute, Stroke Ischemic","enrollment":4000},{"nctId":"NCT06115070","phase":"PHASE4","title":"Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Thrombosis, Acute Ischemic Stroke (AIS)","enrollment":390},{"nctId":"NCT02398656","phase":"PHASE3","title":"A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2015-04-01","conditions":"Stroke, Acute","enrollment":1274},{"nctId":"NCT06352632","phase":"PHASE3","title":"ACT-GLOBAL Adaptive Platform Trial for Stroke","status":"RECRUITING","sponsor":"The George Institute","startDate":"2024-09-26","conditions":"Stroke","enrollment":20000},{"nctId":"NCT04086147","phase":"PHASE2","title":"CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2019-12-09","conditions":"Stroke","enrollment":86}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"low-dose tenecteplase intravenous thrombolysis","genericName":"low-dose tenecteplase intravenous thrombolysis","companyName":"Southwest Hospital, China","companyId":"southwest-hospital-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose tenecteplase is a fibrin-specific thrombolytic agent that converts plasminogen to plasmin, dissolving blood clots in acute ischemic stroke. Used for Acute ischemic stroke within therapeutic window.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}